A study testing the addition of VX-970 (inhibitor drug) to approved chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer, Peritoneal, and Fallopian Tube Cancer (Expansion Cohort)

IRB/UVA Tracking #
21077
Principal Investigator
Linda R Duska
Contact
Anne Gabel
Contact Email
Contact Phone
434.982.6657
Official Trial Title
Phase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine with or without M6620 (VX-970) in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Study Description

The UVA Cancer Center has a clinical trial for women ages 18 and over, who have recurrent platinum-sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.

The purpose of the phase 1 expansion cohort of this trial is to test the addition of the drug, M6620 (VX-970), to the standard chemotherapy treatment of carboplatin and gemcitabine to determine whether the addition of M6620 is more effective than carboplatin and gemcitabine alone.

The overall trial does not have a set duration, your participation in this study will continue as long as your doctor feels like the treatment is helping you.

If eligible and you choose to take part in this clinical trial, the research-related tests and procedures and the M6620 (VX-970) drug and administration of it will be supplied at no charge while you take part in this study.
All other standard clinical procedures, such as the cost of the carboplatin and gemcitabine would be billed to you or your insurance company.

Additional information can be found here: NCT02627443

Compensation

No Compensation